GelMEDIX partners with Catalent to advance vision-restoring cell therapies

The biotechnology company will tap into Catalent’s expertise in induced pluripotent stem cells and advanced cell-therapy manufacturing

iRegene doses first US Parkinson’s patient, launches landmark MSA trial in China

The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration

Axol Bioscience acquires ophthalmology business from Newcells Biotech

Acquisition expands Axol’s portfolio of iPSC-derived retinal organoid and retinal pigment epithelium (RPE) models

Hesperos and Bayer Consumer Health develop frst human-on-a-chip model of stress-induced cognitive dysfunction

New study presents a human-relevant stress model for assessing potential therapeutics

CiRA, Kyoto University and Astellas Phase 2 research agreement signed for iPS Cells

CiRA, Kyoto University and Astellas - Second Phase Joint Research Agreement Signed for Medical Applications of iPS Cells

CellOrigin Biotech collaborates with Qilu Pharma to develop CAR-iMAC Cell Therapy

Gut microbiome as a tool in regenerative medicine

Novel approach driven by GN Corp Japan with potentials in neurological illnesses

EdiGene and Neukio collaborate to develop next-generation immune cell therapies

The collaboration will leverage EdiGene’s expertise in high-throughput genome editing screening and Neukio’s strength in the development and manufacturing of induced pluripotent stem cell (iPSC) and natural killer cell (NK Cell)

DefiniGen promotes Dr Chris Kirton to CEO

The appointment is key for DefiniGEN as they expand the service portfolio to encompass compound screening

Bayer and Mammoth Biosciences to collaborate on gene editing technology

Under the terms of the agreement, Mammoth Biosciences will receive an upfront payment of USD 40 million, potential future payments of more than one billion USD upon successful achievement of certain research, development, and commercial milestones